PFE

Pfizer
D

PFE

Arincen59/100B

Pfizer shares outstanding 1985–2026

Pfizer had 5,699,670,000 shares outstanding on 6 November 2026. Pfizer had 5.72B diluted shares on average over the last twelve months, up 0.1% on the twelve months before. In fiscal year 2025 the average was 5.69B.

Last updated 3 Nov 2026 · Next report 2 Feb 2027

Shares outstanding

Change on the year

Fiscal yearPeriod endingShares outstandingChange on the yearBasic shares
TTM27 Sept 20265.72B+0.15%5.69B
FY202531 Dec 20255.69B-0.25%5.68B
FY202431 Dec 20245.70B-0.16%5.66B
FY202331 Dec 20235.71B-0.42%5.64B
FY202231 Dec 20225.73B+0.44%5.61B
FY202131 Dec 20215.71B+1.35%5.60B
FY202031 Dec 20205.63B-0.76%5.56B
FY201931 Dec 20195.68B-5.05%5.57B
FY201831 Dec 20185.98B-1.34%5.87B
FY201731 Dec 20176.06B-1.64%5.97B
FY201631 Dec 20166.16B-1.57%6.09B
FY201531 Dec 20156.26B-2.60%6.18B
FY201431 Dec 20146.42B-6.83%6.35B
FY201331 Dec 20136.90B-8.16%6.81B
FY201231 Dec 20127.51B-4.60%7.44B
FY201131 Dec 20117.87B-2.53%7.82B
FY201031 Dec 20108.07B+14.61%8.04B
FY200931 Dec 20097.05B+4.37%7.01B
FY200831 Dec 20086.75B-2.72%6.73B
FY200731 Dec 20076.94B-4.61%6.92B
FY200631 Dec 20067.27B-1.85%7.24B
FY200531 Dec 20057.41B-2.67%7.36B
FY200431 Dec 20047.61B+4.50%7.53B
FY200331 Dec 20037.29B+16.74%7.21B
FY200231 Dec 20026.24B-1.89%6.16B
FY200131 Dec 20016.36B-0.11%6.24B
FY200031 Dec 20006.37B+0.81%6.21B
FY199931 Dec 19996.32B+60.39%6.13B
FY199831 Dec 19983.94B-0.34%3.79B
FY199731 Dec 19973.95B+2.43%3.82B
FY199631 Dec 19963.86B+2.20%3.71B
FY199531 Dec 19953.77B+1.52%3.77B
FY199431 Dec 19943.72B-3.85%3.72B
FY199331 Dec 19933.87B-4.61%3.87B
FY199231 Dec 19924.05B+1.07%3.86B
FY199131 Dec 19914.01B+5.15%3.80B
FY199031 Dec 19903.82B-10.37%3.82B
FY198931 Dec 19894.26B+2.21%4.26B
FY198831 Dec 19884.16B+2.58%4.16B
FY198731 Dec 19874.06B-1.58%4.06B
FY198631 Dec 19864.13B-0.38%4.13B
FY198531 Dec 19854.14B—4.14B

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,EPS,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Pfizer's shares

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.